Oncocyte Jumps, Anixa Should Benefit

Shares in Oncocyte (OCX) are up over 200% today. This move is on the back of positive results from their liquid biopsy diagnostic for...

Anixa Doesn’t Disappoint…

On Thursday January 24th, Anixa Biosciences held an investor update call. In the preview to the call, management had talked about 2019 being a...

Anixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance

Tailwinds' Take: excellent news for ANIX. Their CAR-T therapy, being developed in partnership with Moffitt Cancer Center, has not only shown efficacy in ovarian...

Anixa Biosciences to Hold Conference Call to Discuss Outlook for 2019

Tailwinds' Take: we are very excited for this call. "Transformative" is the key word from this press release as it hints at major successes...

Anixa Call On January 24th Could Be Catalyst

When last we spoke with Anixa, they had just finished meeting with the FDA to discuss their Cchek program. The Company has scheduled a...

Tailwinds Top 8 Surprises for 2019

Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the...

The Answer To The Question

Well, I must have been very bad this year as it appears Santa Claus isn't coming to town. The market is trying...

Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic...

Tailwinds' Take: this is a positive development as ANIX moves towards potentially having a diagnostic product during 2019. Our opinion is that...

Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast...

Tailwinds' Take: more positive data just before they meet with the FDA. Important notes from the data include potential "Phase 0" detection and the...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor...

Tailwinds' Take: expecting more positive data out of Cchek. Big meeting with FDA in December will tell us how quickly this product can come...

Anixa Biosciences Presents Positive Data from its A.I. Powered Liquid Biopsy

SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Anixa Biosciences to Present at SITC Annual Meeting

Tailwinds' Take: Anixa continues to demonstrate nothing but very positive results, so expect more from this presentation. We continue to believe the risk /...

As They Start Approaching the FDA, We Discuss Anixa’s Two Innovative Programs

In recent weeks, Anixa has met with the FDA regarding their CAR-T therapy and has now scheduled a discussion around Cchek for early December....

Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic...

Tailwinds' Take: very positive development getting Cchek in front of the FDA for preliminary discussions, especially how quickly the meeting was accepted. With two...

Moffitt Cancer Center and Anixa Biosciences Announce Completion of Pre-IND Meeting with FDA for...

Tailwinds' Take: although this is a minor delay from previous (best case) guidance, it is still fabulous news that Anixa expects to have a...

Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference

Tailwinds' Take: This is outstanding data. The detection of cancer remains in line with prior releases, but the ability to detect benign versus malignant...

Anixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek™ Artificial Intelligence based...

Tailwinds' Take: with two products approaching FDA submissions for clinical trials, ANIX is positioned for significant catalysts and value generation over the next few...

Anixa Biosciences Appoints Leading Researchers in Immuno-Oncology to its Scientific Advisory Board

Tailwinds' Take: this group of SAB members includes scientists who are working on Anixa's CAR-T therapy, which is a major endorsement of the product...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.